Activation of Rictor/mTORC2 signaling acts as a pivotal strategy to protect against sensorineural hearing loss

The Food and Drug Administration–approved drug sirolimus, which inhibits mechanistic target of rapamycin (mTOR), is the leading candidate for targeting aging in rodents and humans. We previously demonstrated that sirolimus could treat ARHL in mice. In this study, we further demonstrate that sirolimu...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Xiaolong, Li, Peipei, Zhang, Linqing, Song, Yuning, An, Yachun, Zhang, Aizhen, Liu, Wenwen, Ye, Chao, Zhang, Yuan, Yue, Rongyu, Sun, Xiaoyang, Chai, Renjie, Wang, Haibo, Gao, Jiangang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917383/
https://www.ncbi.nlm.nih.gov/pubmed/35238644
http://dx.doi.org/10.1073/pnas.2107357119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917383/
https://www.ncbi.nlm.nih.gov/pubmed/35238644
http://dx.doi.org/10.1073/pnas.2107357119

Ejemplares similares